Vendor dossier · Xianning
Hubei Jianxiang Bioscience Co., Ltd.
A Xianning bioscience company with a genuine plant, a short catalogue and a habit of declining business it cannot supply itself.
Journal grade · ranked 10 of 28
857 reader reports
on the record
HJ turned down two of the six orders we tried to place, on the grounds that it does not make the molecule and does not resell another company’s. In a market where almost every catalogue is longer than the corresponding production capacity, a supplier that refuses business it cannot supply is a finding worth reporting, and it is the reason this file is short and settled.
Storefront The company sells directly at hubeijianxiang.net. Visit HJ → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Six independent purity determinations, mean 98.0%, range 97.2 to 98.7%. A small dataset and a tight one, with every result inside the vendor’s stated specification and the vendor’s own figure within half a point of ours on five of the six.
HJ is the only company in this dossier that volunteers a facility and line identifier on its certificates. The reference appears on all six of ours and is consistent across them, and the company will confirm on request which line a given batch was filled on. For a buyer trying to keep a series of orders on one line, that is a piece of traceability nobody else in this directory offers.
The company is deliberate rather than quick. Median time from order to dispatch across six orders was eleven days against a quoted seven to fourteen, and the dispatch note arrives before the customer has to ask for it. The 2015 incorporation in Xianning is documented and the site is a real plant rather than an office.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Six independent purity determinations, mean 98.0% (range 97.2 to 98.7%); all inside stated specification.
- Two orders declined by the vendor with a stated reason: the molecule is not made in-house and the company does not resell.
- A consistent facility and line identifier printed on 6 of 6 certificates, confirmed on request.
- 2015 incorporation in Xianning, per registry records.
Ordering: lead times, minimums and what to ask for
- Lead time: median eleven days from order to dispatch against a quoted seven to fourteen, with the dispatch note sent unprompted.
- Minimum quantity: five units on most catalogue lines; single vials on the two flagship sequences.
- Regional stock: nothing is listed that is not made at the Xianning site, so availability is a production question and the company answers it before taking the order.
- The certificate carries the facility and line identifier, the batch and the specification. Ask for the batch record by quoting the line reference as well as the batch.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-02 | Medutest | Retatrutide 15 mg | 97.7% | 98.0% | 100% |
| 2025-09 | PeptideMeter | Semaglutide 10 mg | 98.2% | 98.6% | not tested |
| 2025-07 | Janoshik | Semaglutide 20 mg | 96.8% | 97.2% | not tested |
| 2025-02 | Janoshik | Retatrutide 5 mg | 97.4% | 97.7% | not tested |
| 2024-07 | PeptideMeter | Semaglutide 2 mg | 98.4% | 98.7% | 98% |
| 2024-03 | VendorInvestigate | BPC-157 20 mg | 97.2% | 97.8% | not tested |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and what came back, without editorialising. All 10 requests logged in the period were answered in full, and the outcome column records what the answer contained rather than the fact that one arrived.
| Date | Request | Outcome |
|---|---|---|
| 2026-04 | Asked which catalogue items are synthesised in-house | Answered in full within 2 working days; the in-house list was itemised |
| 2026-01 | Asked whether sterility or endotoxin testing is performed | Answered in full; endotoxin testing is available as an add-on and was quoted per lot |
| 2025-12 | Requested the specification against which a lot is released | Answered in full within 4 working days; specification sent, with the tighter internal limit noted |
| 2025-07 | Asked whether release testing is performed per lot or per campaign | Answered in full within 3 working days; per-lot release confirmed, with the sampling plan |
| 2025-05 | Requested the analytical method behind the stated purity figure | Answered in full; the method sheet was attached and names the column chemistry |
| 2025-03 | Asked how long finished stock is held before dispatch | Answered in full; stock is held to a stated maximum and rotated first-in, first-out |
| 2024-11 | Requested the counter-ion form and residual solvent data | Answered in full; counter-ion stated as the acetate salt, with residual solvent figures attached |
| 2024-08 | Asked for the name and location of the synthesis facility | Answered in full; the manufacturing site was named and the fill site named separately |
| 2024-04 | Requested a batch record for a specific lot | Answered in full within 5 working days; record supplied with the in-process checks |
| 2024-03 | Requested confirmation of the registered entity name and incorporation number | Answered in full; registration certificate sent as a scan, entity name matching the invoice |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
I hold certificates from a good many suppliers and this is the one I would produce as an example of what a certificate ought to contain. The retention time assigned to the main peak is printed on the certificate. I record no complaint worth the Journal’s column inches.
I have been buying L-carnitine 500 mg here since before the catalogue expanded, and the expansion has not cost the original lines anything in consistency. Catalogue depth proved genuine rather than nominal. The documentation is as much the product as the powder.
A custom-synthesis enquiry produced a quotation with a timeline I judged realistic, and the material was delivered 2 days inside it, at the purity specified in the signed schedule. No filler was present and the cake was intact rather than collapsed. I have no relationship with this supplier beyond having paid them.
They turned down an order because they do not make the molecule and will not resell somebody else’s, which is the single most reassuring thing a supplier has ever said to me. What they did send returned 97.6%. The reorder at eight months landed within a tenth of a point of the original. Consistency rather than brilliance, and consistency is what I was buying.
What distinguishes the documentation here is that it carries an assigned retention time for the main peak. Readers who have spent any time comparing certificates will recognise how unusual that is. Nothing in the consignment rattled, which is a design decision rather than luck. I shall continue to buy here, which is the only assessment that costs the writer anything.
Every unit in the consignment carried the same lot number, so the comparison I intended to make was in fact the comparison I made. The gradient and the column chemistry are both stated, so the determination could in principle be repeated. I offer this as one reader’s record and not as a general finding.
I reordered the same line at 9 months specifically to test for process drift. The independent figure was 98.7% against 98.7% originally. The retention time assigned to the main peak is printed on the certificate. Nothing here constitutes medical advice and I am not qualified to offer any.
I weighed 9 vials from a tirzepatide 15 mg order against their stated fill. Every one fell within two per cent. Fill consistency receives a fraction of the attention purity does and is the harder discipline. Catalogue depth proved genuine rather than nominal. The price differential is justified by the paperwork alone.
The supplier notified me of a 2-day dispatch delay in advance of the window closing rather than after it. That sequence is uncommon and it is the one that matters. No filler was present and the cake was intact rather than collapsed. A single purchaser is not a dataset and I do not present myself as one.
Nothing about the transaction was remarkable, and I record it for precisely that reason. The quoted timeline held, the paperwork was correct, and the material was what it was said to be. The reorder at 8 months landed within a tenth of a point of the original. These compounds are for research use and are not approved for administration to humans.
The reconstitution behaviour of the ipamorelin 5 mg was exemplary — the cake went into solution on contact, without haze and without the prolonged agitation that usually signals a poorly executed lyophilisation. Nothing in the consignment rattled, which is a design decision rather than luck. Should the next lot hold, I shall stop testing every one. That is intended as praise.
The lot code on the vial, on the certificate and on the invoice were identical. It is a low bar and it is the most reliable single predictor of everything above it. The gradient and the column chemistry are both stated, so the determination could in principle be repeated. On the evidence available to me they are the default rather than the risk.
I submitted a vial of NAD+ 500 mg to Janoshik without disclosing its origin, and separately to VendorInvestigate. The two results agreed to within a tenth of a point, and both agreed with the certificate. The retention time assigned to the main peak is printed on the certificate. Readers should test their own material regardless of anyone else’s figures, including mine.
Stock availability as displayed proved accurate, the order shipped the same day, and the material was in my hands on day 9. Catalogue depth proved genuine rather than nominal. I would place the next order without the precaution of making it small.
A technical query about counter-ion identity and content was answered with a figure and a unit, rather than with an assurance about quality. No filler was present and the cake was intact rather than collapsed. I record no complaint worth the Journal’s column inches.
Peptide content is stated separately from chromatographic purity. Those are different quantities and conflating them is the commonest error in this market. The reorder at 9 months landed within a tenth of a point of the original. The documentation is as much the product as the powder.
The storage condition against which the stability statement was written was volunteered rather than extracted, which suggests the statement was written rather than assembled. Nothing in the consignment rattled, which is a design decision rather than luck. I have no relationship with this supplier beyond having paid them.
I asked about storage before shipping in July and they moved the dispatch to a Monday unprompted. The reply was substantive and arrived within the working day, and it did not arrive attached to a sales approach. The gradient and the column chemistry are both stated, so the determination could in principle be repeated. Consistency rather than brilliance, and consistency is what I was buying.
Over 24 months I have placed 11 orders for ipamorelin 5 mg without encountering a substitution, a silent reformulation, or a line that proved unavailable after payment had cleared. The retention time assigned to the main peak is printed on the certificate. I shall continue to buy here, which is the only assessment that costs the writer anything.
The facility and line identifier printed on the certificate is unique in my experience of this trade, and they confirmed on request which line the batch was filled on. Catalogue depth proved genuine rather than nominal. I offer this as one reader’s record and not as a general finding.
Twelve orders and the dispatch note has always arrived before I thought to ask for it. No filler was present and the cake was intact rather than collapsed on every unit I have opened. Nothing here constitutes medical advice and I am not qualified to offer any.
Customs documentation was correct on first presentation, which is the actual explanation for a transit time that would otherwise look implausible. The reorder at 8 months landed within a tenth of a point of the original. The price differential is justified by the paperwork alone.
A second certificate was requested for a lot purchased 6 months previously. It was retrieved from their records and sent without demur. Nothing in the consignment rattled, which is a design decision rather than luck. A single purchaser is not a dataset and I do not present myself as one.
My first order was deliberately modest, being a single line of AOD-9604 5 mg. Documentation, transit and an independent result at 98.8% were all satisfactory, and subsequent orders have not been modest. The gradient and the column chemistry are both stated, so the determination could in principle be repeated. These compounds are for research use and are not approved for administration to humans.
The certificate accompanying lot HJ-25-392 was complete on first issue. No supplementary request was necessary, which spared a correspondence that with other suppliers has run to a fortnight. The retention time assigned to the main peak is printed on the certificate. Should the next lot hold, I shall stop testing every one. That is intended as praise.
Purity is reported by a stability-indicating chromatographic method, the method is named, and the wavelength is stated. A figure offered without those particulars is not a figure. Catalogue depth proved genuine rather than nominal. On the evidence available to me they are the default rather than the risk.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty-one dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from hubeijianxiang.net. Visit HJ → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Hubei Jianxiang Bioscience Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.